Oral TQB3473 Achieves a 56.8% Response Rate in Relapsed/Refractory ITP – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Bingjie Ding et al, adding:
”TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study
This phase 1 trial found oral TQB3473 achieved a 56.8% response rate in relapsed/refractory ITP, with 600 mg daily showing the best efficacy-tolerability balance.”
Title: TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study
Authors: Bingjie Ding, Tiejun Gong, Xiangzhou Du, Xiaoming Li, Yinghui Lai, Zhenyu Yan, Rong Fu, Xin Du, Anqi Yang, Jiajia Zhu, Yiran Wang, Hu Zhou
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 30, 2026, 22:28Recent Mechanical Risk Factors and Young-Onset Cryptogenic Ischemic Stroke – American Heart Association International
-
Sep 30, 2026, 22:22Expert Consensus on Inferior Vena Cava Thrombosis – Thrombosis and Haemostasis Journal
-
Sep 30, 2026, 22:21Markus Abeln: How Platelets, Coagulation, Glycosylation, and Complement Regulate Placental Blood Flow
-
Sep 30, 2026, 22:19Fatma Al Arbawi: Studying Blood Clot Mechanics to Understand Aspirin Resistance and Thrombosis
-
Sep 30, 2026, 22:17Sudhir Kumar: Stroke is a Medical Emergency – and Every Minute Matters
-
Sep 30, 2026, 22:15Luisa Medeiros Visentini: Our Research on Cognitive Impairment After CVT Cited in the International Journal of Stroke
-
Sep 30, 2026, 21:50Jagat Narula: Connecting Cardiovascular Health and Sickle Cell Disease on World Heart Day 2026
-
Sep 30, 2026, 21:38John Kastelein: Exploring the Biology of Cardiovascular Disease at BioCentury Grand Rounds Europe
-
Sep 30, 2026, 21:36Mark Murphy: Irish Heart Foundation Meets With Senator Teresa Costello on World Heart Day